Publication

Return On Investment From Immunization Against 10 Pathogens In 94 Low- And Middle-Income Countries, 2011–30

Authored by:

Sim, S. Y., Watts, E., Constenla, D., Brenzel, L., & Patenaude, B. N.

Full Citation:

Sim, S. Y., Watts, E., Constenla, D., Brenzel, L., & Patenaude, B. N. 2020. Return On Investment From Immunization Against 10 Pathogens In 94 Low- And Middle-Income Countries, 2011–30. Health Affairs. 39(8).

View Publication

Additional key concepts from this publication:

Investing in immunization programs in the world’s poorest countries yields a significant return on the initial investment.

By preventing illness, disability, premature death, lost wages, and other costs, this modeling study found that vaccines against ten pathogens averted $828.5 billion of economic burden in 94 low- and middle-income countries between 2021 and 2030. Immunization programs provided a high return on investment (ROI), with projections for net benefits of vaccine programs estimated at $1,445.3 billion (using a cost-of-illness approach) and $3,371.5 billion (using a value-of-a-statistical-life approach) from 2011 to 2030. For every $1 invested in immunization, there was a return on investment of $20 using cost-of-illness and $52 using a value-of-a-statistical-life approach.